Advances in™ PARP Inhibitors: Expanding the Application of Novel Agents in Ovarian Cancer

Release Date: February 28, 2020
Expiration Date: February 28, 2021
Media: Internet - based

Activity Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of ovarian cancer, with a forward-looking perspective on the expanding role of PARP inhibitors and how novel treatment strategies might impact clinical practice. The changing ovarian cancer treatment landscape is discussed in a multimedia format that includes a series of video interviews with an expert thought leader integrated with text-based elements.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AstraZeneca and Merck.

Target Audience

This educational program is directed toward medical oncologists, gynecologic oncologists, pathologists, radiation oncologists, and surgical oncologists. Other allied healthcare professionals, including nurse practitioners, physician assistants, nurses, and other healthcare professionals involved in the treatment and management of patients with ovarian cancer, will also be invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Examine key safety and efficacy data from clinical trials that have evaluated PARP inhibitors in the management of ovarian cancer
• Review the expanding role of PARP inhibitors in ovarian cancer management, including potential combinations and rationale supporting the role of these combinations
• Discuss the rationale and emerging data sets supporting utilization of immunotherapeutic strategies, including immune checkpoint inhibitors, in ovarian cancer management
• Utilize strategies to minimize potential toxicities and improve tolerability with current and emerging therapies

Faculty, Staff, and Planners’ Disclosures

Faculty

Bradley J. Monk, MD, FACS, FACOG
Professor
Division of Gynecologic Oncology
Arizona Oncology (US Oncology Network)
University of Arizona College of Medicine
Creighton University School of Medicine at St. Joseph’s Hospital
Medical Director
US Oncology Research Network - Gynecologic Program
Phoenix, AZ

Disclosures: Consultant: AbbVie, Advaxis, Agenus, Amgen, Aravive, AstraZeneca, Asymmetric Therapeutics, Boston Biomedical, Chemocare, ChemoID, Circulogene Theranostics, Clovis Oncology, Conjupro Bio-Pharmaceuticals, Eisai, Geistlich Pharma N.A., Genmab/Seattle Genetics, GOG Foundation, ImmunoGen, Immunomedics, Incyte, Janssen/Johnson & Johnson, Laekna Healthcare, Mateon Therapeutics (formerly OXiGENE), Merck, Mersana Therapeutics, Myriad Genetics, NuCana, OncoMed Pharmaceuticals, OncoQuest, OncoSec Medical, Perthera, Pfizer, Precision Oncology, Puma Biotechnology, Regeneron Pharmaceuticals, Roche/Genentech, Samumed, Takeda, Tesaro/GlaxoSmithKline, VBL Therapeutics , Vigeo Therapeutics; Speaker: AstraZeneca, Clovis Oncology, Janssen/Johnson & Johnson, Roche/Genentech, Tesaro/GlaxoSmithKline.

The staff of Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER^® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER^® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER^® is required by ACCME to resolve all COI. PER^® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or the company that provided commercial support.